Reviews/Chronic Spontaneous Urticaria Treatment/Barzolvolimab mast cell depletion in chronic spontaneous urticaria
Novel Biologics · CSU-BIO-04 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Barzolvolimab is an antibody that blocks KIT, a receptor mast cells need to survive. In a placebo-controlled trial in chronic spontaneous urticaria, patients on the drug had markedly fewer hives and itch over seven days than those on placebo [1]. A separate trial in a different kind of urticaria, chronic inducible urticaria, directly measured the drug clearing mast cells from skin and found symptoms improved on the same timetable [8]. An early study in healthy people showed the drug drives down a mast-cell blood marker, pointing to body-wide mast-cell loss [12]. Both parts of the claim are backed by direct data, but the trial that measured skin mast cells and symptoms together was small and uncontrolled and in a different disease, while the main symptom trial did not itself count mast cells in those patients. The panel therefore treated the two halves as supported but bridged across different patient groups.
The corpus shows a placebo-controlled phase 2 trial in CSU with significant UAS7 improvement from baseline to week 12 at all doses versus placebo [1], including complete response (UAS7 = 0) in 22.9%, 51.1%, and 37.5% of dosed patients versus 6.4% for placebo [1]. An open-label CIndU trial reported significant depletion of skin mast cells, tryptase below the limit of detection, and clinical improvement whose kinetics mirrored mast-cell and tryptase reduction through Week 12 [8]. A phase 1a healthy-volunteer study showed profound, dose-dependent suppression of plasma tryptase, a marker associated with tissue mast-cell burden, indicating systemic mast-cell ablation [12]. The depletion half and the symptom half are each supported by primary data, and only [8] measures both in the same patients. The contested point: The division is whether a compound claim demonstrated across three different populations — CSU [1], CIndU [8], and healthy volunteers [12] — reads as one coherent effect. The single study joining mast-cell depletion to symptom relief in the same people [8] is uncontrolled, N=20, and in a different urticaria subtype than the index CSU indication.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is compound and assembled across studies: the RCT-grade symptom data [1] do not themselves measure mast-cell depletion in those CSU patients, so the depletion half rests on [8] and [12] in different populations (CIndU, healthy volunteers).
The only study showing direct skin-MC depletion together with symptom reduction [8] is open-label, uncontrolled, N=20, and in chronic inducible urticaria rather than CSU.
Where it remains uncertain. The one study linking depletion to symptom relief in the same patients [8] is open-label, uncontrolled, N=20, and in CIndU rather than CSU; the CSU symptom trial [1] does not itself measure mast-cell depletion.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT-grade evidence that barzolvolimab reduces urticaria symptoms (UAS7) in CSU
“we assessed the efficacy and safety of various dose regimens of barzolvolimab, a mast cell-depleting anti-KIT antibody, in patients with CSU.”
Panel auditInternal validity: high · scope of inference: Adults with antihistamine-refractory CSU (UAS7 ≥16), symptom outcomes at week 12.Key limitations: abstract reports symptom end points, not direct mast-cell histology · 12-week horizon · phase 2 dose-finding
Direct histologic evidence of skin mast-cell depletion in urticaria patients
“The kinetics of clinical activity mirrored that of MC and tryptase reduction.”
Panel auditInternal validity: medium · scope of inference: Antihistamine-refractory cold urticaria and symptomatic dermographism (CIndU, not CSU), single 3 mg/kg dose, 12-week follow-up.Key limitations: open-label, no placebo · n=20 clinical · inducible rather than spontaneous urticaria
Confirms systemic mast-cell depletion mechanism of barzolvolimab in humans
“CDX-0159 led to dose-dependent, profound suppression of plasma tryptase, a MC-specific protease associated with tissue MC burden, indicative of systemic MC suppression or ablation.”
Panel auditInternal validity: medium · scope of inference: Healthy human volunteers; pharmacodynamic mast-cell suppression only, no disease symptoms.Key limitations: healthy volunteers, no urticaria patients · tryptase surrogate not direct symptom data · speaks only to depletion half
3 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Convergent primary RCT and trial evidence support both mast-cell depletion and urticaria symptom reduction, but phase 2 scope and reliance on an uncontrolled CIndU study to bridge the two halves keep it below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Depletion and symptoms in the same CSU patients. The depletion half and symptom half are demonstrated in different populations; no CSU study measures both. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled CSU trial pairing serial skin mast-cell histology with UAS7 in the same patients.
Open question: Does barzolvolimab deplete skin mast cells in CSU patients, and does that depletion track their symptom improvement? Why it is still open: The CSU trial [1] measured symptoms but not mast cells; the matched-kinetics depletion data come from CIndU [8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19